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Renal involvement in Henoch-Scho¨nlein purpura: A multivariate anal-
ysis of prognostic factors. This study is the first report in which the
relationship between the progression of renal involvement in Henoch-
Scho¨nlein purpura (HSP) and various factors was evaluated using a
multivariate analysis. Sixty-five (33.5%) of 194 patients with HSP devel-
oped renal involvement from three days to 17 months after the onset of
the disease. The plasma coagulation factor XIII (F XIII) activity of 97
patients was examined, and 51 (54.3%) of them showed a decreased
activity. A univariate analysis showed that an age at the onset of more than
seven years, persistent purpura and a decreased F XIII activity all
increased the risk of developing renal involvement. A Cox regression
model analysis indicated severe abdominal symptoms, persistent purpura
and decreased F XIII activity to be significant risk factors and their hazard
ratios were 3.26, 11.53 and 2.27, respectively. Corticosteroid treatment had
a hazard ratio of 0.36 and was considered to decrease the risk of
developing renal involvement. Based on these findings, patients who have
the risk factors for renal involvement should be treated with corticoste-
roids at the onset of the disease to prevent developing renal involvement.
Henoch-Scho¨nlein purpura (HSP) is a systemic vasculitis, char-
acterized by cutaneous purpura, abdominal pain and bleeding,
arthritis and renal involvement. Renal involvement has been
reported to occur in 30% to 80% of the patients with HSP [1].
Most such patients with renal involvement have a good prognosis.
However, some patients do develop end-stage renal disease [2],
and renal involvement in HSP is one of the major causes of
chronic renal failure in children [3]. Therefore, the progression of
renal involvement is considered to contribute to the outcome of
HSP. There have been some reports in which the renal involve-
ment in HSP has been associated with several factors, such as the
age at onset, abdominal symptoms, the recurrence of purpura, and
the treatment with corticosteroids and plasma coagulation factor
XIII (F XIII) concentrate [1, 2, 4–8]. However, these previous
reports all demonstrated problems with the statistical analysis.
Although correlations were observed between various factors in
HSP, the results were only evaluated by univariate analyses. An
univariate analysis cannot accurately justify the relationship be-
tween renal involvement and various factors. Therefore, in order
to elucidate independent risk factors among the various factors in
HSP regarding the development of renal involvement, we evalu-
ated the relationship between renal involvement and various
factors in HSP, using both univariate and multivariate analyses.
METHODS
One hundred and ninety-four patients with HSP (97 boys, 97
girls) who demonstrated no abnormalities on an urinary exami-
nation at the onset of the disease, visited our hospital between
April 1988 and March 1995. The age at the onset ranged from 1.5
to 14.5 years, with a mean (6 SD) of 6.3 6 2.7 years. A diagnosis
of HSP was made if the major manifestations of the illness
consisted of a purpuric rash and abdominal pain without throm-
bocytopenia. Additional features including arthritis and nephritis
were accepted as being consistent with the diagnosis [9]. Any
patients referred with renal involvement were excluded. The
patients with the following symptoms were thus determined to
have severe symptoms: those who could not walk due to arthritis
and those with bloody stool. Recurrent purpura persisting for one
month or more was classified as persistent purpura. Renal involve-
ment was defined by the presence of gross or microscopic
hematuria (.5 cells per high power field from a centrifuged
specimen) either with or without proteinuria [10]. At onset, the F
XIII activity was examined in 97 patients using Berichrom F XIII
(Behringwerke, Marburg, Germany), and the activity of less than
70% was determined to be decreased [11]. Seventy-nine patients
received corticosteroid treatment for relief of abdominal symp-
toms and arthritis. Oral prednisolone was administered at a dose
of 1 mg/kg per day for 1 to two weeks or intravenous hydrocor-
tisone at a dose of 5 mg/kg, four to six times per day for three to
five days, followed by oral prednisolone of 1 mg/kg per day for one
to two weeks. Fourteen of these 79 children were also treated with
F XIII concentrate at a dose of 30 to 50 units/kg per day for three
days. The patients were followed-up for a mean duration of 14.5 6
12.3 months (range 1.0 to 76.1 months).
Statistical analyses was performed using the chi square test or t
test. We analyzed the relationship between the duration after the
onset of the disease and the rate of renal involvement using the
Kaplan-Meier method. We evaluated the potential factors of
renal involvement, using both the generalized-Wilcoxon test for a
univariate analysis and the Cox regression model for a multivar-
iate analysis [12]. A P value of less than 0.05 was thus considered
as significant.
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RESULTS
Clinical features
All 194 patients had purpura, but, in 34 of them, the purpura
appeared only after either abdominal symptoms or arthritis. One
hundred and twenty-one (62.4%) had purpura for more than one
month. Arthritis occurred in 140 (72.2%) and severe joint symp-
toms were present in 47 of these patients. Abdominal symptoms
were evident in 111 (57.2%) while severe abdominal symptoms
were seen in 29 of these patients. Sixty-five (33.5%) developed
renal involvement three days to 17 months after the onset of the
disease. Four developed nephrotic syndrome. Acute renal failure
was noted in one of these four patients, but this patient later
completely recovered. A decreased F XIII activity was found in 51
(52.6%) of the 97 patients examined. Between these 97 patients
who had the examination of F XIII activity and the remaining
patients who did not have the examination, there was no differ-
ence in terms of sex, the age at the onset and the frequency of
severe arthritis, severe abdominal symptoms, persistent purpura,
renal involvement and the treatment with steroids.
The relationship between the duration after the onset of HSP
and the rate of renal involvement is shown in Figure 1. The rate
of renal involvement at one month, three months, six months and
one year after the onset was 16.5%, 26.6%, 31.2%, 35.4%,
respectively. In addition, one child developed renal involvement
17 months after the onset of disease.
Univariate analysis
We evaluated the relationship between renal involvement and
various factors using a univariate analysis as shown in Table 1. An
age of more than seven years at onset (P 5 0.025), persistent
purpura for over one month (P 5 0.0001) and a decreased F XIII
activity (P 5 0.035) were significant risk factors for the progres-
sion of renal involvement. Figure 2 shows a comparison of the
rates of renal involvement between the patients over and under
seven years of age at onset. Figure 3 shows a comparison between
the patients with a decreased F XIII activity and those with a
normal F XIII activity. In the patients with a decreased F XIII
activity, the rate of renal involvement at three months and one
year after the onset was 37.6% and 42.8%, respectively, while in
the patients with a normal F XIII activity it was 17.4% and 25.4%,
respectively.
Multivariate analysis
We analyzed the data of 97 patients in whom the F XIII activity
was determined using the Cox regression model, as shown in
Table 2. Severe abdominal symptoms (P 5 0.034), persistent
purpura (P 5 0.0017) and decreased F XIII activity (P 5 0.046)
were thus found to be independent risk factors for renal involve-
ment with statistical significance, and their hazard ratios were
3.26, 11.53 and 2.27, respectively. Corticosteroid treatment had a
hazard ratio of 0.36 (P 5 0.037) and was considered to decrease
the risk for developing renal involvement independently. Signifi-
cant relationships were found between some factors, and the chi
square and P values between the various factors of these 97
patients are listed in Table 3.
Persistent purpura occurred more frequently in older patients
than in younger ones. Persistent purpura was evident in 48 of the
61 patients over seven years of age at onset, while it was only
evident in 73 of the 133 patients under seven years of age (P 5
0.0015). As shown in Table 1, 54 of the 121 patients with persistent
purpura had renal involvement, and the rate of renal involvement
was not different between the two age groups (Fig. 4A). Only
eleven of the 73 patients without persistent purpura developed
renal involvement, and there was no difference in the prevalence
of renal involvement between the two age groups (Fig. 4B).
DISCUSSION
The present study is the first report in which the relationship
between the development of renal involvement in HSP and
Fig. 1. Relationship between the duration after the onset of Henoch
Scho¨nlein purpura (HSP) and the rate of renal involvement.
Fig. 2. A comparison of the rate of renal involvement between the
patients over or under seven years of age at the onset [(grey line) X, the
patients < 7 years of age; (solid line) Y, the patients > 7 years of age].
Table 1. A univariate analysis of the risk factors of renal involvement
of Henoch Scho¨nlein purpura (HSP)
Risk factor N
Renal
involvement P
Boys 97 31 0.92
Age at the disease onset $7 years 61 26 0.025
Severe arthritis 47 14 0.37
Severe abdominal symptoms 29 13 0.26
Persistent purpura 121 54 0.0001
Decreased F XIII activitya 51 22 0.035
Treatment with steroids 79 26 0.46
Treatment with F XIII concentrate 14 8 0.078
a The number of patients in whom the factor XIII (F XIII) activity was
examined totaled 97
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various factors was evaluated using a multivariate analysis. In our
study, the Cox regression model analysis indicated that severe
abdominal symptoms, persistent purpura and decreased F XIII
activity were independent risk factors of renal involvement with
statistical significance, and also showed the effectiveness of corti-
costeroids for preventing renal involvement.
Sixty-five (33.5%) of 194 patients developed renal involvement
in the present study. Since the patients referred with renal
involvement were excluded, the incidence of renal involvement
was similar to those of previous reports in which the incidence of
renal involvement in unselected children with HSP was 20 to 28%
[13, 14]. There are evidences for racial variability in the incidence
of HSP. High incidence of HSP in Native Americans [15] and low
incidence in African American [4] were reported, although all of
our patients were Japanese children.
In 1977, Henriksson, Hender and Nilsson [16] first reported
that F XIII activity decreased during the acute phase period of
HSP. Kamitsuji et al [17] described the F XIII activity to have a
predictive value in the abdominal symptoms of HSP. Dalens et al
[18] described that patients with severe complications including
nephritis had a lower F XIII activity than the patients without any
complications or with only mild complications. However, the
number of patients was small in their study. In our study, the
number of the patients was larger than theirs and both univariate
and multivariate analyses indicated that a decreased F XIII
activity was one of the risk factors for the progression of renal
involvement in HSP. F XIII treatment has been reported to be
effective for the improvement of abdominal and joint symptoms in
HSP [6, 19]. Fukui et al [6] described that F XIII concentrate
administration improved both proteinuria and hematuria in HSP
nephritis. However, we cannot definitively confirm the effective-
ness of F XIII concentrate administration in preventing the renal
involvement in HSP, because only 14 patients in our study
received this treatment. Yoshioka et al [20] reported that the F
XIII activity decreased in children with acute poststreptococcal
glomerulonephritis, HSP nephritis and rapidly progressive glo-
merulonephritis. Kamitsuji et al [21] showed the deposition of F
XIII in the glomeruli of children with various renal diseases
including HSP nephritis. Decreased F XIII activity may thus result
from the enhanced fibrin formation in the kidney [20].
Previous studies [2, 4] reported that the renal involvement in
HSP occurred more frequently in older children than in younger
children. Our study also indicated that the age at onset was one of
the significant risk factors of renal involvement based on a
univariate analysis (Table 1 and Fig. 2). In spite of this result, a
multivariate analysis did not show that the age at onset was
associated with renal involvement (Table 2). When we divided our
patients into two groups, that is, the patients with and without
persistent purpura, no difference was seen in the rate of renal
involvement between the patients either aged over or under seven
years of age among the two groups (Fig. 4). These results thus
indicate that the age at the onset is not a risk factor of renal
involvement, but instead it is very closely associated with persis-
tent purpura (Table 3).
Previous studies described that the use of corticosteroids gave
the patients with HSP an earlier resolution of their abdominal and
joint symptoms [9, 22]. In contrast those findings, thus far only a
few reports regarding the effect of corticosteroids in preventing
renal involvement have been published [5, 7, 10]. Buchanec and
co-workers [5] described that nephropathy occurred only in one
(4.3%) of 23 patients with predonisone; it occurred in five (50%)
of ten without predonisone in their retrospective study. A pro-
spective study of Mollica et al [7] described that none of 84
patients treated with corticosteroids had renal involvement,
whereas 12 (14.3%) of 84 patients who did not receive corticoste-
roids developed renal involvement from 2 to 72 weeks after
experiencing an acute episode. In contrast to these findings,
Saulsbury [10] stated that corticosteroid therapy did not prevent
nephritis in HSP. However, his conclusion is considered to be due
to the non-random selection of his patients in which corticoste-
roids were given to clinically selected patients who probably were
more severely affected [8].
In our study, a univariate analysis was not able to show that
corticosteroids had any effect on the renal involvement in HSP.
The incidence of renal involvement was almost the same in
patients who received steroids (32.9%) versus patients who did
not receive steroids (33.9%). In spite of this similar incidence of
renal involvement, there was a difference in clinical features
between the two groups. Twenty-three of 79 patients who received
steroids had severe abdominal symptoms, while only six of 115
patients who did not receive steroids had abdominal symptoms
(P , 0.0001). Since the manifestation of abdominal symptoms was
thought to be one of the risk factors of renal involvement [1, 4], we
believe that the corticosteroid treatment decreased the risk of
renal involvement in at least those patients with severe symptoms.
This may be the reason that the univariate analysis failed to
Fig. 3. A comparison of the rate of renal involvement between the
patients with normal and decreased F XIII activity [(grey line) X, the
patients with normal F XIII activity; (solid line) Y, the patients with
decreased F XIII activity].
Table 2. A multivariate analysis of the risk factors of renal involvement
of Henoch Scho¨nlein purpura (HSP; N 5 97)
Risk factor
Hazard
ratio
95% Confidence
interval P
Boys 0.95 0.43–2.13 0.91
Age at the disease onset $7 years 1.64 0.77–3.48 0.61
Severe arthritis 0.53 0.18–1.60 0.26
Severe abdominal symptoms 3.26 1.09–9.69 0.034
Persistent purpura 11.49 2.50–52.63 0.0017
Decreased F XIII activity 2.27 1.02–5.05 0.046
Treatment with steroids 0.36 0.14–0.94 0.037
Treatment with F XIII concentrate 0.95 0.26–3.44 0.94
F XIII is factor XIII.
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indicate the significance of severe abdominal symptoms and the
treatment with steroids. Multivariate analysis certified the signif-
icance of this beneficial effect of corticosteroids in preventing
renal involvement. However, our study was retrospective, and the
aim of the corticosteroid treatment was not to prevent renal
involvement, and, in addition, the corticosteroid administration
was not standardized. Mollica et al [7] recommended that treat-
ment with prednisone (1 mg/kg per day) for all patients with HSP
should be initiated at the beginning of the disease presentation.
However, in view of the intrinsically favorable course of the
purpura nephritis, the study of Glassock, Cohen and Adler [23]
found that aggressive management is not generally indicated. We
also believe that not all patients with HSP should be given
corticosteroids. However, the patients demonstrating risk factors
for developing renal involvement, such as severe abdominal
symptoms, persistent purpura and a decreased F XIII activity,
should be treated with corticosteroids at the onset of the disease.
In addition to that group, patients over seven years of age who
have persistent purpura frequently should be treated with corti-
costeroids, because it is difficult to know beforehand how long the
purpura will persist.
In summary, a multivariate analysis indicated that severe ab-
dominal symptoms, persistent purpura and a decreased F XIII
activity increased the hazard of renal involvement in HSP, while
corticosteroid treatment decreased the risk of such involvement.
The effectiveness of F XIII concentrate administration in prevent-
ing renal involvement could not be elucidated in our study,
because the number of the patients receiving this treatment was
too small. The present study was retrospective and the aim of
corticosteroid treatment was therefore not to prevent renal in-
volvement. Further prospective and/or controlled studies among
more patients are thus necessary in order to justify the need of
corticosteroid treatment for preventing renal involvement in HSP,
and to evaluate the effect of administration of F XIII concentrate.
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Fig. 4. Influence of age at onset on the patients with or without persistent purpura [(solid line) X, the patients < 7 years of age; (grey line) Y, the
patients > 7 years of age]. (A) Patients with persistent purpura (N 5 121), the age at onset of HSP did not influence the development of renal
involvement (P 5 0.13). (B) patients without persistent purpura (N 5 73), the rate of renal involvement was also not influenced by the age at onset
(P 5 0.97).
Table 3. Chi square values (first number) and P values (second number) between each factor (N 5 97)
Risk factor a b c d e f g h
a Boys — — — — — — — —
— — — — — — — —
b Age at the disease onset $7 years 0.76 — — — — — — —
0.38 — — — — — — —
c Severe arthritis 0.00 1.18 — — — — — —
0.99 0.28 — — — — — —
d Severe abdominal symptoms 0.27 0.31 1.23 — — — — —
0.60 0.58 0.27 — — — — —
e Persistent purpura 0.32 6.16 0.00 0.26 — — — —
0.57 0.013 0.97 0.61 — — — —
f Decreased F XIII activity 0.55 0.20 1.06 2.38 0.32 — — —
0.46 0.65 0.30 0.12 0.57 — — —
g Treatment with steroids 0.00 0.02 0.04 10.75 0.22 0.13 — —
0.97 0.89 0.84 0.001 0.64 0.72 — —
h Treatment with F XIII concentrate 5.24 0.26 1.47 16.78 7.05 6.18 18.08 —
0.022 0.61 0.23 ,0.0001 0.008 0.013 ,0.0001 —
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